Centrus Vitality Corp. (NYSE:LEU) is one in all the best performing mid cap stocks so far in 2025. On June 20, Centrus Vitality introduced that the US Division of Vitality/DOE exercised an choice to increase its Excessive-Assay, Low-Enriched Uranium/HALEU manufacturing contract via June 30, 2026.
This extension is valued at ~$110 million and signifies a continuation of the partnership initiated in 2019 to re-establish America’s uranium enrichment capabilities. The prolonged contract’s Part I used to be accomplished in late 2023 with the supply of 20 kilograms of HALEU. Part II required Centrus to provide a further 900 kilograms of HALEU by June 30 this yr, and Centrus produced over 920 kg up to now. The present extension kicks off Part III, which initially included 3 non-obligatory 3-year extension durations for annual manufacturing of 900 kilograms of HALEU UF6.
Picture by Markus Distelrath from Pixabay
Centrus Vitality Corp. (NYSE:LEU) provides nuclear gasoline parts for the nuclear energy trade within the US, Belgium, Japan, the Netherlands, and internationally.
Whereas we acknowledge the potential of LEU as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
